Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kotaro Shide

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Blood Cancer Discovery|October 18, 2021
Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1Junji Koya, Yuki Saito, Takuro Kameda, et al.
Cell Stem Cell|May 21, 2024
SDHAF1 confers metabolic resilience to aging hematopoietic stem cells by promoting mitochondrial ATP productionShintaro Watanuki, Hiroshi Kobayashi, Yuki Sugiura, et al.
Annals of Hematology|November 9, 2023
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosisKotaro Shide, Katsuto Takenaka, Akira Kitanaka, et al.
Blood|November 15, 2014
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease acceleratorTakuro Kameda, Kotaro Shide, Takumi Yamaji, et al.
Blood Advances|January 4, 2018
Hmga2 collaborates with <i>JAK2</i>V617F in the development of myeloproliferative neoplasmsKoki Ueda, Kazuhiko Ikeda, Takayuki Ikezoe, et al.
International Journal of Hematology|March 11, 2025
Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practiceAyako Kamiunten, Takuro Kameda, Masaaki Sekine, et al.
Blood|May 3, 2011
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasmKotaro Shide, Takuro Kameda, Vadim Markovtsov, et al.
International Journal of Hematology|July 25, 2012
Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, JapanTakuya Matsunaga, Kiyoshi Yamashita, Yoko Kubuki, et al.
BMC Infectious Diseases|January 17, 2024
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriersTakuro Kameda, Atae Utsunomiya, Nobuaki Otsuka, et al.
Haematologica|February 15, 2020
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphomaShingo Nakahata, Chilmi Syahrul, Ayako Nakatake, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Blood Cancer Discovery|October 18, 2021
Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1Junji Koya, Yuki Saito, Takuro Kameda, et al.
Cell Stem Cell|May 21, 2024
SDHAF1 confers metabolic resilience to aging hematopoietic stem cells by promoting mitochondrial ATP productionShintaro Watanuki, Hiroshi Kobayashi, Yuki Sugiura, et al.
Annals of Hematology|November 9, 2023
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosisKotaro Shide, Katsuto Takenaka, Akira Kitanaka, et al.
Blood|November 15, 2014
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease acceleratorTakuro Kameda, Kotaro Shide, Takumi Yamaji, et al.
Blood Advances|January 4, 2018
Hmga2 collaborates with <i>JAK2</i>V617F in the development of myeloproliferative neoplasmsKoki Ueda, Kazuhiko Ikeda, Takayuki Ikezoe, et al.
International Journal of Hematology|March 11, 2025
Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practiceAyako Kamiunten, Takuro Kameda, Masaaki Sekine, et al.
Blood|May 3, 2011
R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasmKotaro Shide, Takuro Kameda, Vadim Markovtsov, et al.
International Journal of Hematology|July 25, 2012
Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, JapanTakuya Matsunaga, Kiyoshi Yamashita, Yoko Kubuki, et al.
BMC Infectious Diseases|January 17, 2024
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriersTakuro Kameda, Atae Utsunomiya, Nobuaki Otsuka, et al.
Haematologica|February 15, 2020
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphomaShingo Nakahata, Chilmi Syahrul, Ayako Nakatake, et al.
Pageof 7